Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VIVS vs MTLS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MTLS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–0 Matrix Metrics)

MTLS Overall Winner 6-Pillar Tally: VIVS 0 – 6 MTLS Matrix Metrics: VIVS 0 – 9 MTLS

As of Nov 19, 2026, Materialise NV (MTLS) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas MTLS carries 64.7/100 (BUY) at $6.31 (N/M Forward P/E, 3.4% operating margin).

  • Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile MTLS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIVS vs MTLS
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 5.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18
MTLS NASDAQ Head-to-Head Winner
Materialise NV
Services-Prepackaged Software
$6.31
-0.79% 1D
Market Cap $371.1M
TTM Revenue $605M
Forward P/E N/M
Beta / 30D Vol 1.12β · 87% Vol
Unified Composite Score
64.7 / 100 BUY
Tech 68.0 Fund 66.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 32.7 · SMA20: $7.06 · SMA50: $7.73

6-Pillar Scorecard Institutional Category Breakdown (VIVS 0 – 6 MTLS)

Columns: Metric · VIVS · MTLS
1. Valuation Multiples MTLS
Forward P/E N/M N/M
Trailing P/E N/M 25.0x
PEG Ratio N/M 1.26x
EV / Revenue 9.6x 0.6x
2. Growth & Scale MTLS
Revenue Growth (YoY) -51.4% +2.1%
Earnings Growth (YoY) +0.0% -33.3%
TTM Revenue (USD) $112,000 $605M
Market Cap $2.4M $371.1M
3. Profitability & Quality MTLS
Gross Margin N/A 57.4%
Operating Margin -10117.0% 3.4%
Net Profit Margin 0.0% 4.6%
Return on Equity (ROE) -343.1% 5.0%
4. Balance Sheet & Cash Flow MTLS
Cash Generation (TTM) -$11M EBITDA $55M EBITDA
Cash Flow Margin N/A 9.1% EBITDA Mgn
Net Cash / Leverage $1.4M Net Cash $4.97 Book/Sh · 5.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MTLS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MTLS
OpEx & R&D Intensity N/A 54.0% of Rev ($327M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIVS (0) vs MTLS (9)
Institutional Metric VIVS MTLS Criterion Row Edge
Market Capitalization
Scale
$2.4M $371.1M Larger Scale MTLS
Trailing P/E Ratio
Valuation
N/M 25.0x Lower Multiple MTLS
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-51.4% +2.1% Higher Growth MTLS
Operating Margin (TTM)
Profitability
-10117.0% 3.4% Higher Margin MTLS
Net Profit Margin
Profitability
0.0% 4.6% Higher Margin MTLS
Return on Equity (ROE)
Capital Efficiency
-343.1% 5.0% Higher ROE MTLS
52-Week Range Position
Momentum
5% ($0–$3) 38% ($5–$9) Stronger Trend MTLS
Beta / 30D Volatility
Risk Regime
0.83β · 480% Vol 1.12β · 87% Vol Lower Realized Risk MTLS
Unified Institutional Score
Composite Signal
39.0 / 100 (SELL) 64.7 / 100 (BUY) Higher Composite MTLS
Trailing 12M Revenue (USD)
Operating Scale
$112,000 $605M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 57.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev 1.26x PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.4M Net Cash) $55M EBITDA ($4.97 Book/Sh · 5.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +90.19 pp
VIVS: +64.69% · MTLS: -25.5%
3M Horizon VIVS +6.46 pp
VIVS: +1.92% · MTLS: -4.54%
6M Horizon MTLS +86.67 pp
VIVS: -78.25% · MTLS: +8.42%
1Y Horizon MTLS +88.44 pp
VIVS: -86.99% · MTLS: +1.45%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIVS vs MTLS. Trailing 12-month operating profitability (VIVS -10117.0% vs MTLS 3.4%) and valuation multiples (VIVS N/M vs MTLS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VIVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$112,000
Gross MarginN/A
Op. Margin-10117.0%
ROE / Fwd P/E-343.1% · N/M
MTLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$605M
Gross Margin57.4%
Op. Margin3.4%
ROE / Fwd P/E5.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTLS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MTLS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $371.1M market capitalization and 3.4% operating margin.
OpEx & R&D Reinvestment 54.0% of Rev ($327M)
90D Engineering Disclosures 0 Published

Investor FAQ VIVS vs MTLS Key Questions & Quantitative Answers

As of Nov 19, 2026, Materialise NV (MTLS) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas MTLS carries 64.7/100 (BUY) at $6.31 (N/M Forward P/E, 3.4% operating margin). Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile MTLS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MTLS leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with MTLS at +2.1% YoY revenue growth and -33.3% YoY earnings growth on $605M TTM revenue (57.4% gross margin, 3.4% operating margin). On trailing 12-month operating scale, VIVS generates $112,000 in USD-normalized revenue versus $605M for MTLS. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus 54.0% of Rev ($327M) (0 disclosures) for MTLS.

MTLS screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas MTLS trades at N/M Forward P/E, 25.0x Trailing P/E, 1.26x PEG, and 0.6x EV/Revenue (9.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus MTLS (5.0% ROE) capital efficiency.

In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, MTLS carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.